Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies

AIMS/INTRODUCTION: The prevalence and pathophysiological background of type 2 diabetes mellitus vary across ethnicities, and can affect treatment responses. Adding lixisenatide to basal insulin (BI) in type 2 diabetes mellitus patients has shown improvements in glycated hemoglobin (HbA1c) and postpr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Fuqiang, Liu, Yuan, Liu, Minzhi, Wu, Guangyu, Zhang, Minlu, Zhang, Xia, Cui, Nan, Yin, Huiqiu, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354505/
https://www.ncbi.nlm.nih.gov/pubmed/33475222
http://dx.doi.org/10.1111/jdi.13504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354505/
https://www.ncbi.nlm.nih.gov/pubmed/33475222
http://dx.doi.org/10.1111/jdi.13504

Ejemplares similares